Eaton Financial Holdings Company LLC Takes $494,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Eaton Financial Holdings Company LLC has acquired a new position in Regeneron Pharmaceuticals, purchasing 941 shares valued at approximately $494,000.
• Regeneron reported quarterly earnings of $12.89 EPS, exceeding estimates of $8.43, with a net margin of 31.37% and revenue of $3.68 billion.
• The company recently declared a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6% and a payout ratio of 8.87%.

Eaton Financial Holdings Company LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 941 shares of the biopharmaceutical company's stock, valued at approximately $494,000.

Several other institutional investors have also added to or reduced their stakes in REGN. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $595.68 on Tuesday. The company's 50-day moving average price is $568.27 and its two-hundred day moving average price is $573.48. The firm has a market cap of $63.14 billion, a P/E ratio of 15.01, a P/E/G ratio of 1.98 and a beta of 0.35. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business posted $11.56 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Canaccord Genuity Group restated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.